Results 61 to 70 of about 66,312 (212)

Antiviral Activity and Safety of Molnupiravir in Healthy Participants Inoculated With Influenza Virus: A Phase 2a, Randomized, Human Challenge Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Influenza viruses cause substantial global morbidity and mortality. Molnupiravir, an orally administered prodrug of β‐D‐N4‐hydroxycytidine, has broad activity against RNA viruses, including influenza. A phase 2a, randomized, two‐part human challenge trial in healthy adults (NCT05818124) was conducted to evaluate molnupiravir for influenza infection. In
Jesse Nussbaum, Alex J. Mann, Laura E. Liao, Tian Zhao, Melissa Bevan, Gillian Gillespie, Vanessa Levine Weissler, Brian M. Maas, Diane Longo, Andrew Catchpole, David W. Hilbert, Carisa De Anda   +11 more
wiley   +1 more source

Climate‐related exposures and seizures in children: A systematic review

Epilepsia, EarlyView.
Abstract Objective Climate‐related exposures, including air pollution, temperature extremes, humidity, and atmospheric conditions, are increasingly recognized as potential seizure triggers. As climate change intensifies, understanding the environmental contributors to pediatric seizure risk has important implications for anticipatory guidance and ...
Caroline Sarpy, Yoon Sik Jung, Carol Mita, Xingyan Wang, Phillip L. Pearl, Maitreyi Mazumdar   +5 more
wiley   +1 more source

Validation of Small-Molecule Entry Inhibitors Targeting the Respiratory Syncytial Virus. [PDF]

ChemMedChem
Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, while effective treatments for acute infection are still limited. We screened small‐molecule RSV entry inhibitors and investigated promising hits through resynthesis and antiviral testing.
Karhan C, Sake SM, Urbanek-Quaing M, Bergamo D, Rückert J, Huang J, Grethe C, Gunesch AP, Kühnel A, Reinecke B, Fischer N, Schulz TF, Pietschmann T, Hirsch AKH.   +13 more
europepmc   +2 more sources

Vaccinations in pregnancy: An update for a changing time

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Maternal immunization is one of the most effective public health interventions to reduce infectious morbidity and mortality in pregnant women, fetuses, and newborns. Despite robust evidence supporting vaccine safety and effectiveness in pregnancy, global uptake has declined following the COVID‐19 pandemic, contributing to resurgent outbreaks ...
Wendy Hodge, Méabh Bhuinneáin, Gelila Goba, Marisa Labovsky, Eliana Amaral, Asma Khalil, David Lissauer, Hema Divakar, Fionnuala M. McAuliffe, Deborah Money, Dharmintra Pasupathy, on behalf of the FIGO Committee on Infections During Pregnancy   +11 more
wiley   +1 more source

A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences

Pathogens, 2019
Respiratory syncytial virus (RSV) is a human respiratory pathogen which remains a leading viral cause of hospitalizations and mortality among infants in their first year of life.
Mansi C. Pandya, Sean M. Callahan, Kyryll G. Savchenko, Christopher C. Stobart   +3 more
doaj   +1 more source

Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults

Human Vaccines & Immunotherapeutics, 2021
SeVRSV is a replication-competent Sendai virus (SeV)-based vaccine carrying the respiratory syncytial virus (RSV) fusion protein (F) gene. Unmanipulated, non-recombinant SeV is a murine parainfluenza virus type 1 (PIV-1) and serves as a Jennerian vaccine
Felicia Scaggs Huang, David I. Bernstein, Karen S. Slobod, Allen Portner, Toru Takimoto, Charles J. Russell, Michael Meagher, Bart G. Jones, Robert E. Sealy, Christopher Coleclough, Kristen Branum, Michelle Dickey, Kristen Buschle, Monica McNeal, Mat Makowski, Aya Nakamura, Julia L. Hurwitz   +16 more
doaj   +1 more source

ONCOLYTIC ACTIVITY OF HUMAN RESPIRATORY SYNCYTIAL VIRUS

Experimental Oncology
Oncolytic viruses (OVs) are emerging as novel tools in cancer therapy. Oncolytic virotherapy offers an attractive therapeutic combination of tumor-specific killing and immune co-stimulation, therefore amplifying the host immune response against tumors.
D, Dahrizal, Ibrahim M, Aziz, Gani Asa, Dudin, R, Bhat   +3 more
openaire   +2 more sources

Prevalence of Influenza Viruses A and B, Adenovirus, Respiratory Syncytial Virus, and Human Metapneumonia Viruses among Children with Acute Respiratory Tract Infection

Advances in Virology
Background. Acute respiratory tract infection (ARTI) is a significant cause of morbidity and mortality among children worldwide. The majority of acute respiratory infections in children are caused by viruses, with respiratory syncytial virus (RSV) being ...
Rana Farzi, Neda Pirbonyeh, Mohammad Rahim Kadivar, Afagh Moattari   +3 more
doaj   +1 more source

Trends in hospitalizations for vaccine‐preventable diseases in the United States from 2014 to 2024

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Vaccination rates have declined in recent years, resulting in outbreaks of vaccine‐preventable diseases (VPDs) among children. We aimed to evaluate VPD hospitalization rates from 2014 to 2024 and to report associated trends in outcomes including intensive care utilization, mortality, readmissions, and costs.
Nathan M. Money, Erin Sullivan, Hannah Rector, Corrie E. McDaniel, Jessica L. Markham, Mersine A. Bryan   +5 more
wiley   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source